Chemed Competitors

Chemed (NYSE:CHE) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Chemed and Laboratory Co. of America, as reported by MarketBeat.com.

Chemed currently has a consensus target price of $557.50, indicating a potential upside of 25.22%. Laboratory Co. of America has a consensus target price of $235.4667, indicating a potential downside of 1.85%. Given Chemed's stronger consensus rating and higher probable upside, analysts plainly believe Chemed is more favorable than Laboratory Co. of America.

Earnings & Valuation

This table compares Chemed and Laboratory Co. of America's revenue, earnings per share and valuation.

Laboratory Co. of America has higher revenue and earnings than Chemed. Laboratory Co. of America is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Chemed and Laboratory Co. of America's net margins, return on equity and return on assets.

Insider and Institutional Ownership

86.0% of Chemed shares are held by institutional investors. Comparatively, 89.3% of Laboratory Co. of America shares are held by institutional investors. 4.0% of Chemed shares are held by insiders. Comparatively, 0.7% of Laboratory Co. of America shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Chemed has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Summary

Chemed beats Laboratory Co. of America on 8 of the 14 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and Chemed (NYSE:CHE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Quest Diagnostics and Chemed, as reported by MarketBeat.

Quest Diagnostics currently has a consensus target price of $129.00, suggesting a potential upside of 11.60%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Quest Diagnostics.

Earnings & Valuation

This table compares Quest Diagnostics and Chemed's top-line revenue, earnings per share and valuation.

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest Diagnostics and Chemed's net margins, return on equity and return on assets.

Institutional & Insider Ownership

85.7% of Quest Diagnostics shares are held by institutional investors. Comparatively, 86.0% of Chemed shares are held by institutional investors. 1.5% of Quest Diagnostics shares are held by insiders. Comparatively, 4.0% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dividends

Quest Diagnostics pays an annual dividend of $2.24 per share and has a dividend yield of 1.9%. Chemed pays an annual dividend of $1.36 per share and has a dividend yield of 0.3%. Quest Diagnostics pays out 34.1% of its earnings in the form of a dividend. Chemed pays out 9.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 1 consecutive years and Chemed has raised its dividend for 12 consecutive years.

Risk & Volatility

Quest Diagnostics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Summary

Chemed beats Quest Diagnostics on 11 of the 17 factors compared between the two stocks.

DaVita (NYSE:DVA) and Chemed (NYSE:CHE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for DaVita and Chemed, as reported by MarketBeat.

DaVita currently has a consensus target price of $116.40, suggesting a potential upside of 13.97%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than DaVita.

Earnings and Valuation

This table compares DaVita and Chemed's top-line revenue, earnings per share and valuation.

DaVita has higher revenue and earnings than Chemed. DaVita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DaVita and Chemed's net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.7% of DaVita shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 1.0% of DaVita shares are owned by insiders. Comparatively, 4.0% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

DaVita has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats DaVita on 9 of the 14 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Amedisys and Chemed, as reported by MarketBeat.

Amedisys currently has a consensus target price of $274.4615, suggesting a potential upside of 8.21%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Amedisys.

Earnings and Valuation

This table compares Amedisys and Chemed's top-line revenue, earnings per share and valuation.

Chemed has lower revenue, but higher earnings than Amedisys. Chemed is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amedisys and Chemed's net margins, return on equity and return on assets.

Insider & Institutional Ownership

85.9% of Amedisys shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 2.8% of Amedisys shares are owned by insiders. Comparatively, 4.0% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Amedisys has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats Amedisys on 9 of the 14 factors compared between the two stocks.

LHC Group (NASDAQ:LHCG) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for LHC Group and Chemed, as reported by MarketBeat.

LHC Group currently has a consensus target price of $220.00, suggesting a potential upside of 21.07%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than LHC Group.

Earnings and Valuation

This table compares LHC Group and Chemed's top-line revenue, earnings per share and valuation.

Chemed has lower revenue, but higher earnings than LHC Group. Chemed is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LHC Group and Chemed's net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.8% of LHC Group shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 4.8% of LHC Group shares are owned by insiders. Comparatively, 4.0% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

LHC Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats LHC Group on 9 of the 14 factors compared between the two stocks.

AMN Healthcare Services (NYSE:AMN) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Insider & Institutional Ownership

94.6% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 1.4% of AMN Healthcare Services shares are owned by insiders. Comparatively, 4.0% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares AMN Healthcare Services and Chemed's top-line revenue, earnings per share and valuation.

Chemed has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for AMN Healthcare Services and Chemed, as reported by MarketBeat.

AMN Healthcare Services currently has a consensus target price of $76.2857, suggesting a potential upside of 4.69%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's higher probable upside, analysts clearly believe Chemed is more favorable than AMN Healthcare Services.

Profitability

This table compares AMN Healthcare Services and Chemed's net margins, return on equity and return on assets.

Volatility & Risk

AMN Healthcare Services has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats AMN Healthcare Services on 9 of the 13 factors compared between the two stocks.